Saralasin TFA(Synonyms: [Sar1,Ala8] Angiotensin II TFA)

发表于由

Saralasin TFA;(Synonyms: [Sar1,Ala8] Angiotensin II TFA) 纯度: 99.18%

Saralasin ([Sar1,Ala8] Angiotensin II) TFA 是一种竞争性血管紧张素II (angiotensin II) 拮抗剂。Saralasin-TFA 被用来鉴别肾素依赖性 (血管紧张素原性) 高血压。

Saralasin TFAamp;;(Synonyms: [Sar1,Ala8] Angiotensin II TFA)

Saralasin TFA Chemical Structure

规格 价格 是否有货 数量
10;mM;*;1 mL in DMSO ￥6550 In-stock
5 mg ￥3500 In-stock
10 mg ￥5800 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

Saralasin TFA 相关产品

bull;相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • FDA-Approved Drug Library
  • Drug Repurposing Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Neurotransmitter Receptor Compound Library
  • FDA Approved amp; Pharmacopeial Drug Library
  • Angiogenesis Related Compound Library
  • Peptide Library

生物活性

Saralasin ([Sar1,Ala8] Angiotensin II) TFA is a competitive angiotensin II antagonist. Saralasin TFA is used to identify renin-dependent (angiotensinogenic) hypertension[1].

体外研究
(In Vitro)

Saralasin ([Sar1,Ala8] Angiotensin II) TFA is an intravenously administered, competitive antagonist of angiotensin II that is used to identify renin-dependent (angiotensinogenic) hypertension[1].
Saralasin TFA (1 nmol/ml) inhibits cell growth in 3T3 and SV3T3 cells and causes an increase of cellular renin concentration[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Saralasin ([Sar1,Ala8] Angiotensin II) TFA (10 and 30 mg/kg) increases serum renin activity (SRA) in normal, conscious rats from 2.7 to 16.2 and 22.5 ng/ml/hr, respectively, without markedly altering blood pressure or heart rate. n sodium-depleted rats, Saralasin TFA (0.3 mg/kg) increased SRA from 12 to 119 ng/ml/hr and decreased blood pressure by 6%[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

1026.07

Formula

C44H66F3N13O12
Sequence

{Sar}-Arg-Val-Tyr-Val-His-Pro-Ala
Sequence Shortening

{Sar}-RVYVHPA
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro:;

DMSO : 50 mg/mL (48.73 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.9746 mL 4.8730 mL 9.7459 mL
5 mM 0.1949 mL 0.9746 mL 1.9492 mL
10 mM 0.0975 mL 0.4873 mL 0.9746 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂：;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.5 mg/mL (2.44 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.44 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂：;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (2.44 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.44 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂：;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.44 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.44 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献

  • [1]. Weber MA. Saralasin testing for renin-dependent hypertension. Arch Intern Med. 1979;139(1):93‐95.

    [2]. Schelling P, Ganten D, Speck G, Fischer H. Effects of angiotensin II and angiotensin II antagonist saralasin on cell growth and renin in 3T3 and SV3T3 cells. J Cell Physiol. 1979;98(3):503‐513.

    [3]. Campbell WB, Jackson EK, Graham RM. Saralasin-induced renin release: its blockade by prostaglandin synthesis inhibitors in the conscious rat. Hypertension. 1979;1(6):637‐642.